{"id":203721,"name":"PEAR THERAPEUTICS","slug":"pear-therapeutics","state":"MA","country":"United States of America","description":"Prescription digital therapeutics company.","totalSpending":510000,"filings":16,"yearlySpending":[{"year":2019,"income":30000},{"year":2020,"income":160000},{"year":2021,"income":160000},{"year":2022,"income":150000},{"year":2023,"income":10000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"BUD","display":"Budget/Appropriations"}],"firms":["BLUEBIRD STRATEGIES"],"lobbyists":["JOHN BRENNAN"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Increase awareness of clinical use of FDA cleared prescription digital therapeutics and Medicare coverage.","Increase awareness of clinical use of FDA cleared prescription digital therapeutics and Medicare coverage.","Increase awareness of clinical use of FDA cleared prescription digital therapeutics and Medicare coverage.","H.R. 5333, Ensuring Patient Access to Critical Breakthrough Products Act of 2019, as it relates to Medicare coverage.","Increase awareness of clinical use of FDA cleared prescription digital therapeutics and Medicare coverage."]}